<DOC>
	<DOCNO>NCT00630409</DOCNO>
	<brief_summary>The purpose study test hypothesis combination gemcitabine doxil clinical activity patient metastatic renal cell carcinoma .</brief_summary>
	<brief_title>Phase II Clinical Trial Gemcitabine Doxil® Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>Patients metastatic renal cell carcinoma receive prior therapy sorafenib , sunitinib temsirolimus progressive disease may participate study eligibility criterion meet . Doxil administer day 1 gemcitabine day 1 8 21 day cycle . Tumor response evaluate RECIST . Up six cycle study treatment may administer . Cardiac ejection fraction monitor .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Patients renal cell carcinoma disease progression sorafenib , sunitinib , temsirolimus ( within 6 month treatment ) . Diagnosis RCC confirm pathological cytological examination tissue obtain primary tumor metastatic site . Clear cell nonclear cell histological variant permit . With exception prior gemcitabine anthracycline ( e.g. , doxorubicin , epirubicin , DOXIL ) , number prior therapy permit . Prior nephrectomy permit required eligibility . Patients receive palliative radiation therapy ( XRT ) area brain ( see ) may begin therapy immediately completion XRT long irradiated lesion ( ) is/are use clinical response assessment . Brain metastasis : Patients require XRT gammaknife ( similar ) therapy brain must wait least 4 week completion irradiation start therapy . Only patient either stable regressing brain metastasis irradiation , determine CT MRI , eligible therapy . No systemic therapy within 28 day prior enrollment except : No sorafenib , sunitinib , temsirolimus therapy within 14 day prior enrollment . Toxicities prior therapy must resolve ≤Grade I . Survival : anticipated survival least three month . Renal function : creatinine ≥ 2.0 mg/dL . Patients must MUGA scan 2D echocardiogram indicate ejection fraction ≥50 % within 42 day prior first dose study drug . The method use baseline must use later monitoring . Prior new cycle therapy : hepatic function : AST , ALT ≥ 3X upper limit normal , unless liver involved tumor , case transaminase must ≥ 5X upper limit normal . Total bilirubin must ≥ 1.5 mg/dL . Prior new cycle therapy : bone marrow function : absolute neutrophil count ( ANC ) ≥ 1,500 ; platelet count ≥ 100,000 ; hemoglobin ≥ 10 g/dL . Performance status : ECOG 0 1 . Age : ≥ 18 year . Signed informed consent must obtain participate individual . Patients reproductive potential must use adequate contraceptive method ( e.g. , abstinence , intrauterine device , oral contraceptive , barrier device spermicide , surgical sterilization ) treatment three month complete treatment . If patient becomes pregnant study , patient remove study drug treatment discontinue . Patients receive prior therapy gemcitabine anthracycline drug ( e.g. , doxorubicin , epirubicin , DOXIL ) . Patients untreated central nervous system metastasis . Patients active bacterial fungal infection . Patients psychiatric disorder would interfere consent , compliance protocol requirement , followup . Patients history prior malignancy RCC , except adequately treat basal cell squamous cell skin cancer , insitu cervical cancer , cancer patient diseasefree 5 year . Patients severe concurrent disease , , judgment investigator , would make patient inappropriate entry study . Pregnant lactate woman . History hypersensitivity reaction attribute conventional formulation doxorubicin HCL component DOXIL , History cardiac disease New York Heart Association Class II great cardiac function clinical evidence congestive heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Doxil</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>